Searched for
COVIFOR
Unicorns show the light: From fintech and pharma to green energy they are driving solutions even amid the pandemicAmidst this darkness, there was some light shining through our economy. This was the continued rise of entrepreneurship with newly tagged u...- Pharma companies cut remdesivir injection prices on govt intervention: NPPAMinister of State for Chemicals and Fertilisers Mansukh Mandaviya held meetings with drug manufacturers and other stakeholders on April 12 ...
- Hetero launches Favipiravir in India under the brand ‘Favivir’ to treat Covid-19This is the second drug developed by Hetero after Covifor, the generic version of Remdesivir injection to be administered intravenously in ...
- Hetero starts supply of 60,000 vials of generic Remdesvir for treatment of Covid-19 patientsCovifor is the first generic brand of Remdesivir, which is meant for treatment of COVID-19 patients that are adults and children, hospitali...
- Remdesivir makers told to ramp up production by the department of pharmaceuticalsDelhi’s state regulator has written to chemists' association also about illegal imports of Covid-related drugs remdesivir, favipiravir and ...
- Hetero dispatches 10k vials of Remdesivir for Covid-19 treatmentThe Hyderabad-headquartered Hetero said it will dispatch second batch of 10,000 vials of the generic drug in the injectable form (100mg via...
- Hetero Healthcare set to supply its generic COVID-19 drug at Rs 5,400 per vial across IndiaThe company is set to deliver the first set of 20,000 vials in two equal lots of 10,000 each, one of which will be immediately supplied to ...
- Hetero, Cipla to supply generic Remdesivir to hospitals this weekThe recommended course for a Covid-19 patient under oxygen support is five vials. The approved therapy is for moderate to severe patients.
- Hetero gets DCGI nod to launch Remdesivir for Covid-19 treatmentHetero will produce and launch the first generic Remdesivir under Covifor brand in India following positive clinical outcomes under a licen...
Load More
